NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RGNX shares have increased by 16.6% and is now trading at $38.36. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) released its earnings results on Thursday, May, 7th. The biotechnology company reported ($1.08) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.87) by $0.21. The biotechnology company had revenue of $17.60 million for the quarter, compared to analyst estimates of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The firm's quarterly revenue was up 1855.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.89) earnings per share. View Regenxbio's earnings history.

6 equities research analysts have issued 1 year target prices for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they anticipate Regenxbio's share price to reach $68.33 in the next twelve months. This suggests a possible upside of 78.1% from the stock's current price. View analysts' price targets for Regenxbio.

Press coverage about RGNX stock has been trending somewhat negative recently, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Regenxbio earned a media sentiment score of -1.6 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Acceleron Pharma (XLRN), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Immunovant (IMVT), Twist Bioscience (TWST) and Alector (ALEC). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $38.36.

Regenxbio has a market capitalization of $1.43 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]